Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to initiate a Phase 2 clinical trial of Lucid-MS in patients with multiple sclerosis. The trial will be a randomized, double-blind, placebo-controlled study, marking the first time Lucid-MS will be tested in people with MS. This milestone was highlighted in recent editorial coverage by BioMedWire, which underscored the potential of this novel drug candidate.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug designed to inhibit peptidyl arginine deiminase 2 (PAD2). Unlike many existing MS therapies that broadly suppress the immune system, Lucid-MS targets demyelination—the underlying mechanism of MS—by preventing and potentially reversing myelin degradation. This targeted approach could offer a new avenue for treatment, particularly for patients who do not respond adequately to current immunomodulatory therapies.
The drug candidate previously completed Phase 1 testing in healthy volunteers, where it demonstrated favorable safety and tolerability. With FDA clearance, Quantum BioPharma is preparing to advance Lucid-MS into Phase 2 testing, a critical step in evaluating its efficacy in MS patients. The company also has a parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School, involving a PET imaging tracer designed to quantify demyelination. This tool could enhance the ability to monitor disease progression and treatment response, potentially accelerating drug development.
Analyst attention has followed. Rodman & Renshaw initiated coverage of Quantum BioPharma with a Buy rating and an $8 price target, reflecting confidence in the company's pipeline. The BioMedWire editorial also placed Quantum BioPharma alongside other biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology, and neurological diseases. This context suggests that Quantum BioPharma is part of a broader wave of innovation in neurology and immunology.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS. Beyond MS, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and royalty rights of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The FDA clearance for Lucid-MS Phase 2 testing represents a significant step forward for Quantum BioPharma and the MS community. If successful, Lucid-MS could become a first-in-class therapy that addresses demyelination directly, potentially improving outcomes for millions living with MS. For investors, this milestone validates the company's research and development strategy and could drive value as clinical data emerges.
For more information, visit the full press release at https://ibn.fm/cwPHa. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
